Stock Track | AIM Vaccine Soars 30% After Serum-Free Rabies Vaccine Shows Promising Results

Stock Track

Oct 07, 2024

Shares of AIM Vaccine, a leading Chinese vaccine manufacturer, skyrocketed 30% on Monday after the company announced that the Phase 3 clinical trial results for its serum-free rabies vaccine demonstrated good immunogenicity and safety.

Unlike traditional rabies vaccines that contain animal serum, AIM Vaccine's serum-free formulation eliminates the risk of adverse reactions associated with serum proteins. This innovative approach not only enhances the vaccine's safety profile but also positions AIM Vaccine as a frontrunner in the global rabies prevention market.

The positive clinical trial outcome represents a significant milestone for AIM Vaccine, paving the way for regulatory approvals and commercial launch. Investors welcomed the news, propelling the company's stock to new heights, underscoring the market's confidence in AIM Vaccine's ability to deliver innovative and potentially life-saving solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172478995"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172478995\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172478995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172478995","market":"hk","top_or_hot":-1,"title":"Stock Track | AIM Vaccine Soars 30% After Serum-Free Rabies Vaccine Shows Promising Results","media":"Stock Track","content":"<p>Shares of AIM Vaccine, a leading Chinese vaccine manufacturer, skyrocketed 30% on Monday after the company announced that the Phase 3 clinical trial results for its serum-free rabies vaccine demonstrated good immunogenicity and safety.</p>\n\n<p>Unlike traditional rabies vaccines that contain animal serum, AIM Vaccine's serum-free formulation eliminates the risk of adverse reactions associated with serum proteins. This innovative approach not only enhances the vaccine's safety profile but also positions AIM Vaccine as a frontrunner in the global rabies prevention market.</p>\n\n<p>The positive clinical trial outcome represents a significant milestone for AIM Vaccine, paving the way for regulatory approvals and commercial launch. Investors welcomed the news, propelling the company's stock to new heights, underscoring the market's confidence in AIM Vaccine's ability to deliver innovative and potentially life-saving solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AIM Vaccine Soars 30% After Serum-Free Rabies Vaccine Shows Promising Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AIM Vaccine Soars 30% After Serum-Free Rabies Vaccine Shows Promising Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-07 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of AIM Vaccine, a leading Chinese vaccine manufacturer, skyrocketed 30% on Monday after the company announced that the Phase 3 clinical trial results for its serum-free rabies vaccine demonstrated good immunogenicity and safety.</p>\n\n<p>Unlike traditional rabies vaccines that contain animal serum, AIM Vaccine's serum-free formulation eliminates the risk of adverse reactions associated with serum proteins. This innovative approach not only enhances the vaccine's safety profile but also positions AIM Vaccine as a frontrunner in the global rabies prevention market.</p>\n\n<p>The positive clinical trial outcome represents a significant milestone for AIM Vaccine, paving the way for regulatory approvals and commercial launch. Investors welcomed the news, propelling the company's stock to new heights, underscoring the market's confidence in AIM Vaccine's ability to deliver innovative and potentially life-saving solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06660","symbol_name":"艾美疫苗","start_time":0,"source_url":"","article_id":"1172478995","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172478995","pubTimestamp":1728289338,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of AIM Vaccine, a leading Chinese vaccine manufacturer, skyrocketed 30% on Monday after the company announced that the Phase 3 clinical trial results for its serum-free rabies vaccine demonstrated good immunogenicity and safety.Unlike traditional rabies vaccines that contain animal serum, AIM Vaccine's serum-free formulation eliminates the risk of adverse reactions associated with serum proteins. This innovative approach not only enhances the vaccine's safety profile but also positions AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06660":"艾美疫苗"},"translate_title":"股票追踪无血清狂犬病疫苗显示出有希望的结果后AIM疫苗飙升30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06660":1},"content_text":"Shares of AIM Vaccine, a leading Chinese vaccine manufacturer, skyrocketed 30% on Monday after the company announced that the Phase 3 clinical trial results for its serum-free rabies vaccine demonstrated good immunogenicity and safety.\nUnlike traditional rabies vaccines that contain animal serum, AIM Vaccine's serum-free formulation eliminates the risk of adverse reactions associated with serum proteins. This innovative approach not only enhances the vaccine's safety profile but also positions AIM Vaccine as a frontrunner in the global rabies prevention market.\nThe positive clinical trial outcome represents a significant milestone for AIM Vaccine, paving the way for regulatory approvals and commercial launch. Investors welcomed the news, propelling the company's stock to new heights, underscoring the market's confidence in AIM Vaccine's ability to deliver innovative and potentially life-saving solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}